Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring

Clinical Chemistry

Volumn 45, Issue 10, 1999, Pages 1695-1707

  Bidart, Jean Michel ^a   Thuiller, François ^b   Augereau, Christine ^c   Chalas, Jacqueline ^d   Daver, Alain ^e   Jacob, Nelly ^f   Labrousse, Françoise ^g   Voitot, Hélène ^h  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE HOSPITALIER DE MEAUX   (France)

^c Hopital Boucicaut   (France)

^d Hop Antoine Béclère   (France)

^e CENTRE PAUL PAPIN   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g Hopital Laennec   (France)

^h BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ANTIGEN SPECIFICITY; CANCER DIAGNOSIS; DISEASE MARKER; HUMAN; KINETICS; PATIENT MONITORING; PREDICTION; PROTEIN BLOOD LEVEL; REVIEW;

ALPHA-FETOPROTEINS; CA-125 ANTIGEN; CA-15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN; HUMANS; KINETICS; MONITORING, PHYSIOLOGIC; NEOPLASMS; PROSTATE-SPECIFIC ANTIGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 0032850651     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (164)

1. 1. Gion M, Mione R, Barioli P, Dittadi R. Dynamic use of tumor markers, rationale-clinical applications and pitfalls. Anticancer Res 1996;16:2279-84.
2. 2. Wu J, Nakamura R. Human circulating tumor markers, current concepts and clinical applications. Chicago, IL: American Society of Clinical Pathologists, 1997:263pp.
3. 3. Hayes DF, Bast RC, Desch CE, Fritsche H, Kemeny NE, Jessup M, et al. Tumor marker utility system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88: 1456-66.
4. 4. Pamies RJ, Crawford DR. Tumor markers: an update. Med Clin N Am 1996;80:185-99.
5. 5. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992;267: 2215-20.
6. 6. Carter HB, Morrell CH, Pearson JD, Brant LJ, Plato CC, Metter EJ, et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res 1992;52:3323-8.
7. 7. Stamey TA, Dietrick DD, Issa MM. Large, organ confined, impalpable transition zone prostate cancer: association with metastatic levels of prostate specific antigen. J Urol 1993;149: 510-5.
8. 8. Schmid HP, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 1993;71:2031-40.
9. 9. Weber JP, Oesterling JE, Peters CA, Partin AW, Chan DW, Walsh PC. The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia. J Urol 1989;141:987-92.
10. 10. Brawer MK, Aramburu EA, Chen GL, Preston SD, Ellis WJ. The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinoma. J Urol 1993;150:369-73.
11. 11. Stamey TA, Kabalin JN. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients. J Urol 1989;141:1070-5.
12. 12. Zagars GK, Pollack A. The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer. Cancer 1993;72:832-42.
13. 13. Cadeddu JA, Pearson JD, Partin AW, Epstein JI, Carter HB. Relationship between changes in prostate-specific antigen and prognosis of prostate cancer. Urology 1993;42:383-9.
14. 14. Carter HB, Pearson JD. PSA velocity for the diagnosis of early prostate cancer. A new concept. Urol Clin N Am 1993;20:665-70.
15. 15. Hanks GE, D'Amico A, Epstein BE, Schultheiss TE. Prostatic-specific antigen doubling times in patients with prostate cancer: a potentially useful reflection of tumor doubling time. Int J Radiat Oncol Biol Phys 1993;27:125-7.
16. 16. D'Amico AV, Hanks GE, Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer 1993;72:2638-43.
17. 17. Hanks GE, Hanlon AL, Lee WR, Slivjak A, Schultheiss TE. Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior. Int J Radiat Oncol Biol Phys 1996;34:549-53.
18. 18. Pollack A, Zagars GK, Kavadi VS. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer 1994;74:670-8.
19. 19. Oesterling JE, Chan DW, Epstein JI, Kimball AW Jr, Bruzek DJ, Rock RC, et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 1988;139:766-72.
20. 20. Stamey TA, Graves HC, Wehner N, Ferrari M, Freiha FS. Early detection of residual prostate cancer after radical prostatectomy by an ultrasensitive assay for prostate specific antigen. J Urol 1993;149:787-92.
21. 21. Semjonow A, Hamm M, Rathert P. Half-life of prostate-specific antigen after radical prostatectomy: the decisive predictor of curative treatment? Eur Urol 1992;21:200-5.
22. 22. Semjonow A, Hamm M, Rathert P. Prediction of tumor recurrence after radical prostatectomy using elimination kinetics of prostate-specific antigen. World J Urol 1993;11:218-20.
23. 23. van Straalen JP, Bossens MM, de Reijke TM, Sanders GT. Biological half-life of prostate-specific antigen after radical prostatectomy. Eur J Clin Chem Clin Biochem 1994;32:53-5.
24. 24. Semjonow A, Hamm M, Rathert P. Elimination kinetics of prostate-specific antigen in serum and urine. Int J Biol Markers 1994;9:15-20.
25. 25. Lein M, Brux B, Jung K, Henke W, Koenig F, Stephan C, et al. Elimination of serum total and free prostate-specific antigen after radical retropubic prostatectomy. Eur J Clin Chem Clin Biochem 1997;35:591-5.
26. 1-antichymotrypsin in serum. Urology 1998;51:57-62.
27. 27. Ravery V, Meulemans A, Boccon-Gibod L. Clearance of free and total PSA after prostatic surgery. Eur Urol 1998;33:251-4.
28. 28. Haab F, Meulemans A, Boccon-Gibod L, Dauge MC, Delmas V, Boccon-Gibod L. Clearance of serum PSA after open surgery for benign prostatic hypertrophy, radical cystectomy, and radical prostatectomy. Prostate 1995;26:334-8.
29. 29. Brandle E, Gottfried HW, Maier S, Flohr P, Steinbach G, Hautmann RE, [Is radical prostatectomy a suitable model for determination of PSA half-life?]. Urologe A 1995;34:419-23.
30. 30. Morgan WR, Zincke H, Rainwater LM, Myers RP, Klee GG. Prostate specific antigen values after radical retropubic prostatectomy for adenocarcinoma of the prostate: impact of adjuvant treatment (hormonal and radiation). J Urol 1991;145:319-23.
31. 31. Oesterling JE. Andrews PE, Suman VJ, Zincke H, Myers RP. Preoperative androgen deprivation therapy: artificial lowering of serum prostate specific antigen without downstaging the tumor. J Urol 1993;149:779-82.
32. 32. Zagars GK, Pollack A, Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 1997;44:213-21.
33. 33. Vijayakumar S, Quadri SF, Karrison TG, Trinidad CO, Chan SK, Halpern HJ, et al. Localized prostate cancer: use of serial prostate-specific antigen measurements during radiation therapy. Radiology 1992;184:271-4.
34. 34. Zagars GK, von Eschenbach AC. Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy. Cancer 1993;72:538-48.
35. 35. Ritter MA, Messing EM, Shanahan TG, Potts S, Chappell RJ, Kinsella TJ. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J Clin Oncol 1992;10:1208-17.
36. 36. Kaplan ID, Cox RS, Bagshaw MA. Prostate specific antigen after external beam radiotherapy for prostatic cancer: follow-up. J Urol 1993;149:519-22.
37. 37. Fijuth J, Chauvet B, Vincent P, Felix-Faure C, Reboul F. Serum prostate-specific antigen in monitoring the response of carcinoma of the prostate to radiation therapy. Radiother Oncol 1992;23:236-40.
38. 38. Stamey TA, Kabalin JN, Ferrari M, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti- androgen treated patients, J Urol 1989;141:1088-90.
39. 39. Stamey TA, Ferrari MK, Schmid HP. The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients. J Urol 1993;150:1856-9.
40. 40. Morrow CP, Kletzy OA, Disaia PJ, Towsend DE, Mishell DR, Nakamura RM. Clinical and laboratory correlates of molar pregnancy and trophoblastic disease. Am J Obstet Gynecol 1977; 128:424-30.
41. 41. Schlaerth JB, Morrox CP, Kletzy OA, Nalick RH, D'Ablaing GA. Prognostic characteristics of serum chorionic gonadotropin titer regression following molar pregnancy. Obstet Gynecol 1981;58: 478-82.
42. 42. Yedema KA, Verheijen RH, Kenemans P, Schijf CP, Borm GF, Segers MF, et al. Identification of patients with persistent trophoblastic disease by means of a normal human chorionic gonadotropin regression curve. Am J Obstet Gynecol 1993;168:787-92.
43. 43. Mortakis AE, Braga CA. "Poor prognosis" metastatic gestational trophoblastic disease: the prognostic significance of the scoring system in predicting chemotherapy failure. Obstet Gynecol 1990;76:272-7.
44. 44. International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15:594-603.
45. 45. Bidart JM, Bellet D. Human chorionic gonadotropin: molecular forms, detection and clinical implications. Trends Endocrinol Metab 1993;4:285-91.
46. 46. Thompson DK, Haddow JE. Serial monitoring of serum α-fetoprotein and chorionic gonadotropin in males with germ cell tumors. Cancer 1979;43:1820-9.
47. 47. Picozzi VJ, Freiha FS, Hannigan JF, Torti FM. Prognostic significance of a decline in serum chorionic gonadotropin levels after chemotherapy for advanced germ-cell carcinoma. Ann Intern Med 1984;100:183-6.
48. 48. Culine S, Kramar A, Biron P, Droz JP. Chemotherapy in adult germ cell tumors. Crit Rev Oncol Hematol 1996;22:229-63.
49. 49. Germa-Lluch JR, Begent RH, Bagshawe KD. Tumour marker levels and prognosis in malignant teratoma of the testis. Br J Cancer 1980;42:850-5.
50. 50. Gerl L, Lamerz R, Mann K, Clemm C, Wilmanns W. Is serum tumor marker half-life a guide to prognosis in metastatic non-seminomatous germ cell tumors? Anticancer Res 1997;17:3047-9.
51. 51. Stevens MJ, Norman AR, Dearnaley DP, Horwich A. Prognostic significance of early tumor marker half-life in metastatic testicular teratoma. J Clin Oncol 1995;13:87-92.
52. 52. de Wit R, Sylvester R, Tsitsa C, de Mulder PH, Sleyfer DT, ten Bokkel Huinink WW, et al. Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer. Br J Cancer 1997;75: 432-5.
53. 53. Saxman SB, Nichols CR, Foster RS, Messemer JE, Donohue JP, Einhorn LH. The management of patients with clinical stage I nonseminomatous testicular tumors and persistently elevated serologic markers. J Urol 1996;155:587-9.
54. 54. Toner GC, Geller NL, Tan C, Nisselbaum J, Bosl GJ. Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. Cancer Res 1990;50:5904-10.
55. 55. Shirabe K, Takenaka K, Gion T, Shimada M, Fujiwara Y, Sugimachi K. Significance of α-fetoprotein levels for detection of early recurrence of hepatocellular carcinoma after hepatic resection. J Surg Oncol 1997;64:143-6.
56. 56. Johnson PJ, Williams R. Serum α-fetoprotein estimations on doubling time in hepatocellular carcinoma: influence of therapy and possible value in early detection. J Natl Cancer Inst 1980; 64:1329-32.
57. 57. Buamah PK, James OFN, Skillen AW, Harris AL. The value of tumor marker kinetics in the management of patients with primary hepatocellular carcinoma. J Surg Oncol 1988;37:161-4.
58. 58. Kawai M, Furuhashi Y, Kano T, Misawa T, Nakashima N, Hattori S, et al. α-Fetoprotein in malignant germ cell tumors of the ovary. Gynecol Oncol 1990;39:160-6.
59. 59. Walhof CM, Van Sonderen L, Voute PA, Delemarre JF, Half-life of α-fetoprotein in patients with a teratoma, endodermal sinus tumor, or hepatoblastoma. Pediatr Hematol Oncol 1988;5:217-27.
60. 60. Han SJ, Yoo S, Choi SH, Hwang EH. Actual half-life of alpha-fetoprotein as a prognostic tool in pediatric malignant tumors. Pediatr Surg Int 1997;12:599-602.
61. 61. American Society of Clinical Oncology. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996;14:2843-77.
62. 62. Sorokin JJ, Sugarbaker PH, Zamcheck N, Pisick M, Kupchik HZ, Moore FD. Serial carcinoembryonic antigen assays. Use in detection of cancer recurrence, JAMA 1974;228:49-53.
63. 63. Mackay AM, Patel S, Carter S, Stevens U, Laurence DJR, Cooper EH, et al. Role of serial plasma CEA assays in detection of recurrent and metastatic colorectal carcinomas. Br Med J 1974;4:382-5.
64. 64. Sikorska H, Schuster J, Gold P. Clinical applications of carcino-embryonic antigen. Cancer Detect Prev 1988;12:321-55.
65. 65. Minton JP, Martin EW Jr. The use of serial CEA determinations to predict recurrence of colon cancer and when to do a second-look operation. Cancer 1978;42:1422-7.
66. 66. Staab HJ, Anderer FA, Stumpf E, Fischer R. Slope analysis of the postoperative CEA time course and its possible application as an aid in diagnosis of disease progression in gastrointestinal cancer. Am J Surg 1978;136:322-7.
67. 67. National Institutes of Health. Carcinoembryonic antigen: its role as a marker in the management of cancer. A National Institutes of Health Consensus Development Conference. Ann Intern Med 1981;94:407-9.
68. 68. Minton JP, Hoehn JL, Gerber DM, Horsley JS, Connolly DP, Salwan F, et al. Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study. Cancer 1985;55:1284-90.
69. 69. Sugarbaker PH, Gianola FJ, Dwyer A, Neuman NR. A simplified plan for follow-up of patients with colon and rectal cancer supported by prospective studies of laboratory and radiologic test results. Surgery 1987;102:79-87.
70. 70. Chu DZJ, Erickson CA, Russell P, Thompson C, Lang NP. Broadwater RJ, et al. Prognostic significance of carcinoembryonic antigen in colorectal carcinoma. Arch Surg 1991;126:314-6.
71. 71. Staab HJ, Anderer FFA, Stumpf E, Homung A, Fischer R, Kieninger G. Eighty-four potential second-look operations based on sequential carcinoembryonic antigen determinations and clinical investigations in patients with recurrent gastrointestinal cancer. Am J Surg 1985;149:198-204.
72. 72. Moertel CG, Shutt AJ, Go VLW. Carcinoembryonic antigen test for recurrent colorectal carcinoma. Inadequacy for early detection. JAMA 1978;239:1065-6.
73. 73. Steele G Jr, Ellenberg S, Ramming K, O'Connell M, Moertel C, Lessner H, et al. CEA monitoring among patients in multiinstitutional adjuvant Gl therapy protocols. Ann Surg 1982;196:162-9.
74. 74. Boey J, Cheung HC, Lai CK, Wong J. A prospective evaluation of serum carcinoembryonic antigen (CEA) levels in the management of colorectal carcinoma. World J Surg 1984;8:279-86.
75. 75. Denstman F, Rosen L, Khuchandani IT, Sheets J, Stasik JJ, Riether R. Comparing predictive decision rules in postoperative CEA monitoring. Cancer 1986;58:2089-95.
76. 76. Staab HJ, Anderer FA, Hornung A, Stumpf E, Fisher R. Doubling time of circulating CEA and its relation to survival of patients with recurrent colorectal cancer. Br J Cancer 1982;46:773-81.
77. 77. Umehara Y, Kimura T, Yoshida M, Oba N, Harada Y. Comparison of doubling times of serum carcinoembryonic antigen produced by various metastatic lesions in recurrent gastric and colorectal carcinomas. Cancer 1993;71:4055-9.
78. 78. Korenaga D, Saeki H, Mawatari K, Orita H, Maekawa S, Ikeda T, et al. Serum carcinoembryonic antigen concentration doubling time correlates with tumor biology and life expectancy in patients with recurrent gastrointestinal carcinoma. Arch Surg 1997;132:188-94.
79. 79. Takahashi Y, Mai M. Usefulness of sequential post-surgical tumor markers monitoring: prediction of remaining cancers by calculating dissociation from a half life period line. Ann Cancer Res Ther 1993;2:87-9.
80. 80. Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-8.
81. 81. Hine KR, Dykes PW. Prospective randomised trial of early cytotoxic therapy for recurrent colorectal carcinoma detected by serum CEA. Gut 1984;25:682-8.
82. 82. Allen-Mersh TG, Kemeny N, Niedzwiecki D, Shurgot B, Daly JM. Significance of a fall in serum CEA concentration in patients treated with cytotoxic chemotherapy for disseminated colorectal disease. Gut 1987;28:1625-6.
83. 83. Quentmeier A, Schlag P, Hohenberger P, Schwarz V, Abel U. Assessment of serial carcinoembryonic antigen: determinations to monitor the therapeutic progress and prognosis of metastatic liver disease treated by regional chemotherapy. J Surg Oncol 1989;40:112-8.
84. 84. Iwama T, Mishima Y, Sato H. A proposal of indices to describe the carcinoembryonic antigen time course in order to assess the effects of treating recurrent colorectal carcinoma. Jpn J Surg 1990;20:123-6.
85. 85. Hohenberger P, Schlag PM, Gernerth T, Herfath C. Pre- and postoperative carcinoembryonic antigen determinations in hepatic resection for colorectal metastases. Predictive value and implications for adjuvant treatment based on multivariate analysis. Ann Surg 1994;219:135-41.
86. 86. Ward U, Primrose JN, Finan PJ, Perren TJ, Selby P, Purves DA, et al. The use of tumor markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer. Br J Cancer 1993;67:1132-5.
87. 87. van der Burg MEL, Lammes FB, Verweij J. CA 125 in ovarian cancer. Neth J Med 1992;40:36-51.
88. 88. Kenemans P, Yederna CA, Bon GG, Von Mensdorff Pouilly S. CA 125 in gynecological pathology: a review. Eur J Obstet Gynecol Reprod Biol 1993;49:115-24.
89. 89. Makar AP, Kristensen GB, Kaern J, Bormer OP, Abeler VM, Trope CG, et al. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. Obstet Gynecol 1992;6:1002-10.
90. 90. Nagele F, Petru E, Medl M, Kainz C, Graf AH, Sevelda P. Preoperative CA 125. an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1995;86:259-64.
91. 91. Gadducci A, Zola P, Landoni F, Maggino T, Sartori E, Bergamino T, Cristofani R, Serum half life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gynecol Oncol 1995;58:42-7.
92. 92. Mogensen O, Brock A, Nyland MH. CA 125 measurements in ovarian cancer patients during their first postoperative week. Int J Gynecol Cancer 1993;3:54-6.
93. 93. Yedema CA, Kenemans P, Thomas CM, Massuger LF, Wobbes T, Verstraeten R, et al. CA 125 serum levels in the early post operative period do not reflect tumour reduction obtained by cytoreductive surgery. Eur J Cancer 1993;29:966-71.
94. 94. van der Burg MEL, Lammes FB, Van Putten WLJ, Stoter G. Ovarian cancer: the prognostic value of the serum half-life of CA 125 during induction chemotherapy. Gynecol Oncol 1988;30:307-12.
95. 95. Fisken J, Leonard RCF, Stewart M, Beattie GJ, Sturgeon C, Aspinall L, et al. The prognostic value of early CA 125 serum assay in epithelial ovarian carcinoma. Br J Cancer 1993;68:140-5.
96. 96. Willemse HB, Aalders JG, de Bruyn HWA, Mulder NH, Sleijfer DT, de Vries EGE. CA 125 in ovarian cancer: relation between half-life, doubling time and survival. Eur J Cancer 1991;8:993-5.
97. 97. Markowska J, Kopczynski Z, Szewierski Z, Manys G. CA 125 in monitoring chemotherapy of patients with ovarian cancer. Eur J Gynecol Oncol 1990;3:209-14.
98. 98. Markowska J, Manys G, Szewierski Z. CA 125 in monitoring clinical course in ovarian cancer patients. A prospective clinical study. Eur J Gynecol Oncol 1992;2:201-4.
99. 99. Buller RE, Berman ML, Bloss JD, Manetta A, Disaia PJ. CA 125 regression: a model for epithelial ovarian cancer response. Am J Obstet Gynecol 1991;165:360-7.
100. 100. Yedema CA, Kenemans P, Voorhorst F, Bon G, Schijf C, Beex L, et al. CA 125 half-life in ovarian cancer: a multivariate survival analysis. Br J Cancer 1993;67:1361-7.
101. 101. Cruickshank DJ, Terry PB Fullerton WT. The potential value of CA 125 as a tumour marker in small volume, non-evaluable epithelial ovarian cancer. Int J Biol Markers 1991;4:247-52.
102. 102. Hawkins RE, Roberts K, Wiltshaw E, Mundy J, Fryatt U, McCready VR. The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian cancer. Br J Obstet Gynaecol 1989;96:1395-9.
103. 103. Hunter VJ, Daly L, Helms M, Soper JT, Berchuck A, Clarke-Pearson DL, et al. The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol 1990;163:1164-7.
104. 104. Meier W, Stieber P, Fateh-Moghadam A, Eiermann W, Hepp H. [Prognostic significance of the CA 125 half-life for the further outcome of ovarian cancer], Geburtsh Frauenheilkd 1992;52:528-32.
105. 105. Frasci G, Conforti S, Zullo F, Mastrantonio P, Comella G, Comella P, et al. A risk model for ovarian carcinoma patients using CA 125. Cancer 1996;77:1122-30.
106. 106. Buller RE, Berman ML, Bloss JD, Manetta A, DiSaia PJ. Serum CA 125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival. Gynecol Oncol 1992;47:87-92.
107. 107. Buller RE, Vasilev S, Disaia PJ. CA 125 kinetics. A cost effective clinical tool to evaluate clinical trial outcomes in the 1990s. Am J Obstet Gynecol 1996;174:1241-54.
108. 108. Pearl ML, Yashar CM, Johnston CM, Reynolds RK, Roberts JA. Exponential regression of CA 125 during salvage treatment of ovarian cancer with taxol. Gynecol Oncol 1994;53:339-43.
109. 109. Rustin GJS, Nelstrop AE, McClean P, Brady MF, McGuire WP, Hoskins WJ, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996;14:1545-51.
110. 110. Riedinger JM, Barillot I, Coudert B, Fargeot P, Berrioolo-Riedinger A, Guerrin J. Valeur pronostique de la demi-vie initiale du CA 125 mesurée au cours de la chimiothérapie d'induction chez 62 patientes porteuses de tumeur épithéliale ovarienne stade III et IV. Bull Cancer 1996;83:654-63.
111. 111. Schmidt-Rhode P, Schultz KD, Sturm G, Raab-Frick A, Prinz H. CA 15.3 as a tumor marker in breast cancer. Int J Biol Markers 1987;3:33-8.
112. 112. Gion M, Fila G, Biasoli R, Vignati G, Mione R, Saracchini S, et al. Kinetic use of tumor markers in the follow-up of patients operated for primary breast cancer. J Nuclear Med Allied Sci 1990;34:1-7.
113. 113. Dnistrian AM, Schwartz MK, Greenberg EJ, Smith CA, Schwartz DC. CA 15.3 and carcinoembryonic antigen in the clinical evaluation of breast cancer. Clin Chim Acta 1991;200:81-94.
114. 114. Gion M, Ruggeri G, Mione R, Marconato R, Casell A, Nosadini A, et al. A new approach to tumor marker assessment by perioperative determination in breast and colorectal cancer. Int J Biol Markers 1993;1:8-13.
115. 115. Jung K, Stephan C, Lein M, Henke W, Schnorr D, Brux B, et al. Analytical performance and clinical validity of two free prostate-specific antigen assays compared. Clin Chem 1996;42:1026-33.
116. 116. McCormack RT, Rittenhouse HG, Finlay JA, Sokoloff RL, Wang TJ, Wolfert RL, et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology 1995;45:729-44.
117. 117. Aoyagi Y, Saitoh A, Susuki Y, Igarashi K, Oguro M, Yokota T, et al. Fucosylation index of alphafoetoprotein, a possible aid in the early recognition of hepatocellular carcinoma, a possible patients with cirrhosis. Hepatology 1993;17:50-2.
118. 118. Bellet DH, Wands JR, Isselbacher KJ, Bohuon C. Serum α-fetoprotein levels in human disease: perspective from a highly specific monoclonal radioimmunoassay. Proc Natl Acad Sci U S A 1984;81:3869-73.
119. 119. Nap M, Vitali A, Nustad K, Bast RC Jr, O'Brien TJ, Nilsson O, et al. Immunohistochemical characterization of 22 monoclonal antibodies against the CA125 antigen: 2nd report from the ISOBM TD-1 Workshop. Tumour Biol 1996;17:325-31.
120. 120. Sokoloff RL, Wolfert RL, Rittenhouse HG. Standardization of PSA immunoassays: proposals and practical limitations. J Clin Ligand Assay 1995;1886-92.
121. 121. Ferrero JM, Largillier R, Ramaioli A, Heudier P, Teissier E, Namer M. Valeur pronostique de la normalisation précoce du CA 125 au cours de la chimiothérapie des tumeurs de l'ovaire stades III et IV. Bull Cancer 1997;84:722-8.
122. 122. Daoud E, Bodor G, Weaver C, Ladenson JH, Scott MG. CA 125 concentrations in malignant and non malignant disease. Clin Chem 1991;37:1968-74.
123. 123. Ruibal Morell A. CEA serum levels in non-neoplastic diseases. Int J Biol Markers 1992;7:160-6.
124. 124. Liaw YF, Tai Dl, Chen JJ, Chu CM, Huang MJ. α-Fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma. Liver 1986;6:133-7.
125. 125. Oberbauer R, Banyai S, Schmidt A, Kornek G, Scheithauer W, Mayer G. Serum tumor markers after renal transplantation. Transplantation 1996;62:1506-9.
126. 126. Lye WC, Tambyah P, Leong SO, Lee EJ. Serum tumor markers in patients on dialysis and kidney transplantation. Adv Perit Dial 1994;10:109-11.
127. 127. Lopez LA, Del Villar V, Ulla M, Fernandez F, Fernandez LA, Santos I, et al. Prevalence of abnormal levels of serum tumour markers in elderly people. Age Ageing 1996;25:45-50.
128. 128. Wadler S, Schwartz EL, Golman M, Lyver A, Rader M, Zimmerman M, et al. Fluorouracil and recombinant α-2a-interferon; an active regimen against advanced colorectal carcinoma. J Clin Oncol 1989;7:1769-75.
129. 129. Greiner JW, Guadagni F, Goldstein D, Borden EC, Ritts RE Jr, Witt P, et al. Evidence of serum carcinoembryonic antigen and tumor associated glycoprotein-72 in patients administered interferons. Cancer Res 1991;51:4155-63.
130. 130. Ruckle HC, Oesterling JE. Prostate-specific antigen and androgen deprivation therapy. World J Urol 1993;11:227-32.
131. 131. van der Burg MEL, Myles JD, Hoskins PJ, Ten Bokkel Huinink WW, Eisenhauer E. CA125 is an unreliable marker for monitoring response to Taxol therapy in patients with relapsed ovarian cancer [Abstract]. Eur J Cancer 1993;29A:133.
132. 132. Boerman OC, Segers MF, Poels LG, Kenemans P, Thomas CMJMB. Heterophilic antibodies in human sera causing falsely increased results in the CA 125 immunofluorometric assay. Clin Chem 1990;36:888-91.
133. 133. Reinsberg J. Interference by human antibodies with tumor marker assays. Hybridoma 1995;4:205-8.
134. 134. Cruickshank DJ, Paul J, Lewis CR, McAllister EJ, Kaye SB. An independent evaluation of the potential clinical usefulness of proposed CA-125 indices previously shown to be of prognostic significance in epithelial ovarian cancer. Br J Cancer 1992;65:597-600.
135. 135. Rustin GJ, Nelstrop AE, McClean P, Brady MF, McGuire WP, Hoskins WJ, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996;14:1545-51.
136. 136. van der Zee AG, Duk JM, Aalders JG, Boontje AH, ten Hoor KA, de Bruijn HW. The effect of abdominal surgery on the serum concentration of the tumour-associated antigen CA 125. Br J Obstet Gynaecol 1990;97:934-41.
137. 137. Kiang DT, Greenberg LJ, Kennedy BJ. Tumor marker kinetics in the monitoring of breast cancer. Cancer 1990;65:193-9.
138. 138. Stamey TA. Lower limits of detection, biological detection limits, functional sensitivity, or residual cancer detection limit ? Sensitivity reports on prostate specific antigen assays mislead clinicians. Clin Chem 1996;42:849-52.
139. 139. Leaning MS, Gallivan S, Newlands ES, Dent J, Brampton M, Smith DB, Bagshawe KD. Computer system for assisting with clinical interpretation of tumour marker data. Br Med J 1992;305:804-7.
140. 140. Hara M, Koyamagi Y, Inoue T, Fukuyama T. Some physicochemical characteristics of γ-seminoprotein; an antigenic component specific for human seminal plasma. Jpn J Legal Med 1971;25:322-4.
141. 141. Ascheim S, Zondek B. Das Hormon Der Hypophysenvorderlapens: Testobjeckt zum Nachweis des Hormons. Klin Wochenschr 1927;6:248-52.
142. 142. Bergstrand CG, Czar B. Demonstration of a new protein fraction in serum from the human fetus. Scand J Clin Lab Investig 1956;8:1070-7.
143. 143. Armbruster DA. Prostate-specific antigen: biochemistry, analytical methods and clinical application. Clin Chem 1993;39:181-95.
144. 144. Pierce JG, Parsons TF. Glycoprotein hormones: structure and function. Annu Rev Biochem 1981;50:465-95.
145. 145. Deutsch HF, Chemistry and biology of a fetoprotein. Adv Cancer Res 1991;56:253-311.
146. 146. Chu TM, Kawinski E, Hibi N, Crogham G, Wiley J, Killian CS, et al. Prostate-specific antigen domain of human prostate-specific antigen identified with monoclonal antibodies. J Urol 1989;141:151-5.
147. 147. Jameson JL, Hollenberg AN. Regulation of chorionic gonadotropin gene expression. Endocr Rev 1993;14:203-21.
148. 148. Korhonen J, Alfthan H, Ylostalo P, Veldhuis J, Stenman UH. Disappearance of human chorionic gonadotropin and its α- and β-subunits after term pregnancy. Clin Chem 1997;43:2155-63.
149. 149. Keller RH, Lyman S. α-Fetoprotein: biological and clinical potential. In: Rhodes BA, ed. Tumor imaging. New York: Masson Publishing, 1982:41-52.
150. 150. Oesterling JE. Prostate-specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-23.
151. 151. Stenman UH, Bidart JM, Birken S, Mann K, Nisula B, O'Connor J. Standardization of protein immunoprocedures. Choriogonadotropin (CG). Scand J Clin Lab Investig Suppl 1993;216:42-78.
152. 152. Alfthan H, Stenman UH. Pathophysiological importance of various molecular forms of human choriogonadotropin. Mol Cell Endocrinol 1996;125:107-20.
153. 153. Lamerz R. AFP isoforms and their clinical significance. Anticancer Res 1997;17:2927-30.
154. 154. Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinoma by immunological tolerance and adsorption techniques. J Exp Med 1965;21:439-62.
155. 155. Bast RC, Freeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Investig 1981;68:1331-7.
156. 156. Kufe D, Imghirami G, Miyako A. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 1984;3:223-32.
157. 157. Hilkens J, Hilgers J, Buijs F. Monoclonal antibodies against human milk fat globule membranes detecting differentiation antigens of mammary gland and its tumors. Int J Cancer 1984;34:197-206.
158. 158. Thomas P, Toth CA, Saini KS, Jessup JM. Steele G Jr. The structure, metabolism and function of the carcinoembryonic antigen gene family. Biochim Biophys Acta 1990;1032:177-89.
159. 159. Yamashita K, Totami K, Kuroki M, Ueda I, Kobata A. Structural studies of the carbohydrate moieties of carcinoembryonic antigens. Cancer Res 1987;47:3451-9.
160. 160. Siddiqui J, Abe M, Hayes DF, Shani E, Yunis E, Kufe DW. Isolation and sequencing on and cDNA coding for human DF3 breast carcinoma associated antigen. Proc Natl Acad Sci U S A 1988;85:2320-3.
161. 161. Verheist J, Van den Broecke E, Van Meerbeeck J, De Backer W, Blockx P, Vermeire P. Calculation of half-life of carcinoembryonic antigen after lung tumor resection: a case report. Eur Respir J 1991;4:374-6.
162. 162. Hammarstrom S, Shively JE, Paxton RJ, Beatty BG, Larsson A, Ghosh R, et al. Antigenic sites in carcinoembryonic antigen. Cancer Res 1989;49:4852-8.
163. 163. O'Brien T, Raymond LR, Bannon GA, Ford DH, Hardadottir H, Miller FC, et al. New monoclonal antibodies identify the glycoprotein carrying the CA 125 epitope. Am J Obstet Gynecol 1991;165:1857-64.
164. 164. Tobias R, Rothwel C, Wagner J, Green A, Liu YSV. Development and evaluation of radioimmunoassay for the detection of a monoclonal antibody defined breast cancer associated antigen 115D8/DF3 [Abstract]. Proceeding of the Symposium of the American Association for Analytical Clinical Chemistry, 24 July 1985, Atlanta, GA:73-4.